血清淀粉样蛋白A在呼吸系统疾病中的临床应用
The Clinical Use of Serum Amyloid A in Respiratory Diseases
DOI: 10.12677/ACM.2023.13122689, PDF,   
作者: 高 欢：西安医学院研究生工作部，陕西 西安；王水利*：陕西省人民医院呼吸与危重症一科，陕西 西安
关键词: 血清淀粉样蛋白A；新型冠状病毒肺炎；诊断；预后；Serum Amyloid A； Corona Virus Disease 2019； Diagnosis； Prognosis
摘要: 血清淀粉样蛋白A (serum amyloid A, SAA)是由肝脏产生的一组多肽脂蛋白，当机体受到炎性刺激并发生炎症反应时可迅速升高。对于新型冠状病毒肺炎、慢性阻塞性肺疾病急性加重、间质性肺疾病、肺结核、肺癌等呼吸系统疾病的早期诊断、指导治疗、疗效评估有重要的意义。现就SAA在呼吸系统疾病中的临床应用价值方面作一综述。
Abstract: Serum amyloid A (serum amyloid A, SAA) is a group of polypeptide lipoproteins produced by the liver, which can be rapidly increased when the body receives inflammatory stimulation and devel-ops an inflammatory reaction. It is of great significance for the early diagnosis, guiding treatment and efficacy evaluation of respiratory diseases such as COVID-19, acute aggravation of chronic ob-structive pulmonary disease, interstitial lung disease, tuberculosis and lung cancer. The clinical ap-plication value of SAA in respiratory diseases is reviewed.
文章引用：高欢, 王水利. 血清淀粉样蛋白A在呼吸系统疾病中的临床应用[J]. 临床医学进展, 2023, 13(12): 19117-19122. https://doi.org/10.12677/ACM.2023.13122689

参考文献

[1] 李万华, 李正强, 王爱民, 等. 2012-2021年重庆市大足区慢性呼吸系统疾病死亡率及早死疾病负担趋势变化[J]. 实用预防医学, 2023, 30(2): 148-151.
[2] 汪锋, 刘辛. 空气污染与呼吸系统疾病发病率的关系分析[J]. 重庆大学学报, 2021, 44(4): 97-106.
[3] 陈海清, 张雪岷, 惠平, 等. 血清PCT与Hs2CRP和SAA水平在老年慢性阻塞性肺疾病急性加重期下呼吸道感染诊断中的临床意义[J]. 中华医院感染学杂志, 2016, 26(17): 3930-3932.
[4] Sack, G.J. (2018) Serum Amyloid A—A Review. Molecular Medicine, 24, Article No. 46. [Google Scholar] [CrossRef] [PubMed]
[5] Abouelasrar, S.S., Gouwy, M., Van Damme, J., et al. (2021) The Turning Away of Serum Amyloid A Biological Activities and Receptor Usage. Immunology, 163, 115-127. [Google Scholar] [CrossRef] [PubMed]
[6] Zhang, Y., Zhang, J., Sheng, H., et al. (2019) Acute Phase Reactant Serum Amyloid A in Inflammation and Other Diseases. Advances in Clinical Chemistry, 90, 25-80. [Google Scholar] [CrossRef] [PubMed]
[7] Liu, C. (2012) Serum Amyloid a Protein in Clinical Cancer Diag-nosis. Pathology and Oncology Research, 18, 117-121. [Google Scholar] [CrossRef] [PubMed]
[8] He, Y., Ma, C., Xing, J., et al. (2019) Serum Amyloid a Protein as a Potential Biomarker in Predicting Acute Onset and Association with In-Hospital Death in Acute Aortic Dissection. BMC Cardiovascular Disorders, 19, Article No. 282. [Google Scholar] [CrossRef] [PubMed]
[9] Jasim, S.A., Mahdi, R.S., Bokov, D.O., et al. (2022) The Deci-phering of the Immune Cells and Marker Signature in COVID-19 Pathogenesis: An Update. Journal of Medical Virology, 94, 5128-5148. [Google Scholar] [CrossRef] [PubMed]
[10] Zhao, Y., Zhou, S. and Heng, C.K. (2007) Impact of Serum Amyloid A on Tissue Factor and Tissue Factor Pathway Inhibitor Expression and Activity in Endothelial Cells. Arterio-sclerosis, Thrombosis, and Vascular Biology, 27, 1645-1650. [Google Scholar] [CrossRef] 
[11] Beijer, E., Roodenburg-Benschop, C., Schimmelpennink, M.C., et al. (2021) Elevated Serum Amyloid a Levels Are Not Specific for Sarcoidosis but Associate with a Fibrotic Pulmonary Phenotype. Cells, 10, Article No. 585. [Google Scholar] [CrossRef] [PubMed]
[12] Abbas, A.A., Alghamdi, A., Mezghani, S., et al. (2022) Role of Serum Amyloid A as a Biomarker for Predicting the Severity and Prognosis of COVID-19. Journal of Immunology Research, 2022, Article ID: 6336556. [Google Scholar] [CrossRef] [PubMed]
[13] Pieri, M., Ciotti, M., Nuccetelli, M., et al. (2021) Serum Amyloid A Protein as a Useful Biomarker to Predict COVID-19 Patients Severity and Prognosis. International Immunopharmacol-ogy, 95, Article ID: 107512. [Google Scholar] [CrossRef] [PubMed]
[14] Fu, J., Huang, P.P., Zhang, S., et al. (2020) The Value of Serum Amyloid A for Predicting the Severity and Recovery of COVID-19. Experimental and Therapeutic Medicine, 20, 3571-3577. [Google Scholar] [CrossRef] [PubMed]
[15] 任成山, 王关嵩, 钱桂生. 慢性阻塞性肺疾病的成因及其治疗的困惑与希望[J]. 中华肺部疾病杂志(电子版), 2019, 12(2): 127-141.
[16] 支建刚. IL-6、SAA、PCT在COPD伴肺炎患者中的表达意义[J]. 中国医学创新, 2019, 16(20): 134-138.
[17] 叶武, 黄勍栋, 唐婷玉. 血清淀粉样蛋白A在老年慢性阻塞性肺疾病患者合并吸入性肺炎诊断和治疗效果监测中的价值[J]. 中国医药, 2020, 15(6): 868-872.
[18] 王月平, 袁开芬, 王应琼, 等. 外周血SAA、NLR及BNP对COPD合并肺部感染患者预后的评估价值[J]. 贵州医科大学学报, 2020, 45(5): 579-583.
[19] 江颖仪, 李德宪, 劳穗华, 等. 血清淀粉样蛋白A、降钙素原、超敏C反应蛋白检测对肺结核合并肺炎的诊断价值[J]. 南方医科大学学报, 2021, 41(3): 453-458.
[20] 国家感染性疾病临床医学研究中心, 深圳市第三人民医院, 编辑委员会中国防痨杂志. 肺结核活动性判断规范及临床应用专家共识[J]. 中国防痨杂志, 2020, 42(4): 301-307.
[21] Awoniyi, D.O., Teuchert, A., Sutherland, J.S., et al. (2016) Evaluation of Cytokine Responses against Novel Mtb Antigens as Diagnostic Markers for TB Disease. Jour-nal of Infection, 73, 219-230. [Google Scholar] [CrossRef] [PubMed]
[22] Jiang, T.T., Shi, L.Y., Wei, L.L., et al. (2017) Serum Amyloid A, Protein Z, and C4b-Binding Protein Beta Chain as New Potential Biomarkers for Pulmonary Tuberculosis. PLOS ONE, 12, e173304. [Google Scholar] [CrossRef] [PubMed]
[23] Kawka, M., Brzostek, A., Dzitko, K., et al. (2021) Mycobacte-rium Tuberculosis Binds Human Serum Amyloid A, and the Interaction Modulates the Colonization of Human Macro-phages and the Transcriptional Response of the Pathogen. Cells, 10, Article No. 1264. [Google Scholar] [CrossRef] [PubMed]
[24] Ferrian, S., Manca, C., Lubbe, S., et al. (2017) A Combination of Base-line Plasma Immune Markers Can Predict Therapeutic Response in Multidrug Resistant Tuberculosis. PLOS ONE, 12, e176660. [Google Scholar] [CrossRef] [PubMed]
[25] Zhou, J., Sheng, J., Fan, Y., et al. (2018) Association between Serum Amyloid A Levels and Cancers: A Systematic Review and Meta-Analysis. Postgraduate Medical Journal, 94, 499-507. [Google Scholar] [CrossRef] [PubMed]
[26] Lin, H.Y., Tan, G.Q., Liu, Y., et al. (2019) The Prognos-tic Value of Serum Amyloid A in Solid Tumors: A Meta-Analysis. Cancer Cell International, 19, Article No. 62. [Google Scholar] [CrossRef] [PubMed]
[27] du Plessis, M., Davis, T., Loos, B., et al. (2021) Molecular Regu-lation of Autophagy in a Pro-Inflammatory Tumour Microenvironment: New Insight into the Role of Serum Amyloid A. Cytokine & Growth Factor Reviews, 59, 71-83. [Google Scholar] [CrossRef] [PubMed]
[28] Di Noia, V., D’argento, E., Pilotto, S., et al. (2021) Blood Se-rum Amyloid A as Potential Biomarker of Pembrolizumab Efficacy for Patients Affected by Advanced Non-Small Cell Lung Cancer Overexpressing PD-L1: Results of the Exploratory “FoRECATT” Study. Cancer Immunology, Immuno-therapy, 70, 1583-1592. [Google Scholar] [CrossRef] [PubMed]
[29] Wang, Y.S., Chang, H.J., Chang, Y.C., et al. (2013) Serum Amyloid a as a Predictive Marker for Radiation Pneumonitis in Lung Cancer Patients. International Journal of Radiation Oncology, Biology, Physics, 85, 791-797. [Google Scholar] [CrossRef] [PubMed]
[30] Vietri, L., D’alessandro, M., Bergantini, L., et al. (2020) Specific-ity of Serum Amyloid A as a Biomarker of Idiopathic Pulmonary Fibrosis. Internal Medicine Journal, 50, 1571-1574. [Google Scholar] [CrossRef] [PubMed]
[31] Bergantini, L., D’alessandro, M., Vietri, L., et al. (2020) Utility of Serolog-ical Biomarker’ Panels for Diagnostic Accuracy of Interstitial Lung Diseases. Immunologic Research, 68, 414-421. [Google Scholar] [CrossRef] [PubMed]
[32] Beijer, E., Roodenburg-Benschop, C., Schimmelpennink, M.C., et al. (2021) Elevated Serum Amyloid a Levels Are Not Specific for Sarcoidosis but Associate with a Fibrotic Pulmonary Phenotype. Cells, 10, Article No. 585. [Google Scholar] [CrossRef] [PubMed]

为你推荐